Ipamorelin: Full Research Guide, Protocol & Vendor Pricing

The complete researcher's reference on ipamorelin — structure, full GHS-R1a mechanism, clinical history, reconstitution, dosing protocols for standalone and stacked use, desensitization considerations, and current vendor pricing.

Chemistry & Structure

Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Molecular weight: 711.85 Da. The key structural features that confer its selectivity:

• Aib (α-aminoisobutyric acid) at position 1 — prevents enzymatic degradation and contributes to receptor selectivity
• D-2-Nal at position 3 — D-amino acid configuration improves metabolic stability; 2-naphthylalanine provides the hydrophobic bulk needed for GHS-R1a binding
• D-Phe at position 4 — further resistance to proteolytic cleavage
• C-terminal amidation — improves receptor binding affinity and extends half-life versus the free acid form

These modifications produce a peptide with a ~2 hour plasma half-life (significantly longer than native ghrelin at ~30 minutes) and high selectivity for GHS-R1a over other hormone receptors.

Full Mechanism: GHS-R1a Agonism

The GHS-R1a Receptor

The growth hormone secretagogue receptor type 1a (GHS-R1a) is a G-protein coupled receptor expressed primarily in the pituitary, hypothalamus, and several peripheral tissues. When activated, it triggers the IP3/DAG signaling cascade, leading to intracellular calcium mobilization and ultimately GH vesicle release from pituitary somatotrophs.

Selectivity vs Other GHRPs

Older GHRPs like GHRP-2 and GHRP-6 activate GHS-R1a but also engage other receptors — most notably the CD36 scavenger receptor and receptors involved in cortisol and prolactin regulation. Ipamorelin's structural modifications create a binding profile that strongly favors GHS-R1a with minimal off-target activity, which is why cortisol and prolactin remain largely unaffected at research doses.

Pulsatile GH Release

Critically, ipamorelin produces pulsatile GH release rather than continuous elevation. Each injection produces a GH spike over approximately 3 hours, mimicking the body's natural secretory pattern. This is physiologically preferable to continuous GH elevation for several reasons: it preserves receptor sensitivity, maintains IGF-1 within a more natural range, and aligns with how GH actually functions in anabolic and lipolytic signaling.

Clinical Trial History

Ipamorelin was developed by Novo Nordisk in the late 1990s. The primary clinical development program targeted postoperative ileus — slowed return of GI motility after abdominal surgery — based on GHS-R1a receptor expression in the GI tract.

Novo Nordisk discontinued the program after the Phase 2 GI trial missed its endpoint. The compound entered the research supply chain, where its favorable GH selectivity profile has made it one of the most widely studied standalone GHRPs in the field.

Standalone Research Protocol

Some researchers use 2–3x daily dosing (morning fasted, post-workout, and pre-sleep) to maximize total daily GH output. This is a more aggressive protocol and requires larger supply. The single pre-sleep dose is the most commonly used for its simplicity and favorable GH pulse alignment.

CJC-1295 + Ipamorelin Stack Protocol

The combined stack uses CJC-1295 (without DAC) or CJC-1295 with DAC alongside ipamorelin. The choice of CJC variant changes dosing frequency:

Both compounds can be drawn into the same syringe and injected simultaneously — they do not interact chemically. Most research using the combination uses CJC No-DAC (also called Modified GRF 1-29) for more precise control over pulse timing.

Reconstitution Guide

1. Allow vial to reach room temperature (~15 minutes)
2. Draw bacteriostatic water into a syringe — standard is 1–2mL per 10mg vial
3. Inject BAC water slowly down the inner glass wall; do not spray directly onto the powder
4. Swirl gently until dissolved — do not shake
5. At 2mL per 10mg vial: concentration = 5mg/mL = 5,000mcg/mL
6. A 200mcg dose = 0.04mL — use a 1mL insulin syringe for accuracy
7. Store refrigerated at 2–8°C; use within 28 days of reconstitution

Desensitization & Cycling

One of ipamorelin's advantages over GHRP-2 and GHRP-6 is significantly lower receptor desensitization. Older GHRPs show measurable GHS-R1a downregulation with chronic use, requiring cycling to restore sensitivity. Ipamorelin's more selective binding appears to produce less receptor internalization at equivalent GH-stimulating doses.

Most research protocols still cycle to be conservative — 8–12 weeks on, 4 weeks off is common. Longer continuous protocols have been used without apparent loss of efficacy, but systematic human data on optimal cycling is limited.

Side Effect Profile

Ipamorelin's clean receptor selectivity translates to a favorable adverse effect profile:

• Water retention: GH-mediated; mild at research doses. Reducing sodium intake helps.
• Transient flushing/tingling: Reported in a minority of subjects post-injection; typically resolves within 30 minutes.
• Headache: Occasionally reported, especially at higher doses in the first weeks.
• Fatigue/drowsiness: Feature, not bug — beneficial for pre-sleep dosing protocols.
• Injection site reactions: Mild; rotate sites per injection.

No significant cortisol elevation, prolactin elevation, or appetite stimulation at research doses — the key safety differentiators from older GHRPs.

Vendor Pricing